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Abstract
Background: Viral load (VL) monitoring is an essential component of the care of HIV positive individuals. Rates of
VL monitoring have been shown to vary by HIV risk factor and clinical characteristics. The objective of this study
was to determine whether there are differences among regions in Canada in the rates of VL testing of HIV-positive
individuals on combination antiretroviral therapy (cART), where the testing is available without financial barriers
under the coverage of provincial health insurance programs.
Methods: The Canadian Observational Cohort (CANOC) is a collaboration of nine Canadian cohorts of HIV-positive
individuals who initiated cART after January 1, 2000. The study included participants with at least one year of
follow-up. Generalized Estimating Equation (GEE) regression models were used to determine the effect of
geographic region on (1) the occurrence of an interval of 9 months or more between two consecutive recorded
VL tests and (2) the number of days between VL tests, after adjusting for demographic and clinical covariates.
Overall and regional annual rates of VL testing were also reported.
Results: 3,648 individuals were included in the analysis with a median follow-up of 42.9 months and a median of
15 VL tests. In multivariable GEE logistic regression models, gaps in VL testing >9 months were more likely in
Quebec (Odds Ratio (OR) = 1.72, p < 0.0001) and Ontario (OR = 1.78, p < 0.0001) than in British Columbia and
among injection drug users (OR = 1.68, p < 0.0001) and were less likely among older individuals (OR = 0.77 per
10 years, p < 0.0001), among men having sex with men (OR = 0.62, p < 0.0001), within the first year of cART
(OR = 0.15, p < 0.0001), among individuals on cART at the time of the blood draw (OR = 0.34, p < 0.0001) and
among individuals with VL < 50 copies/ml at the previous visit (OR = 0.56, p < .0001).
Conclusions: Significant variation in rates of VL testing and the probability of a significant gap in testing were
related to geographic region, HIV risk factor, age, year of cART initiation, type of cART regimen, being in the first
year of cART, AIDS-defining illness and whether or not the previous VL was below the limit of detection.
Background
Viral load (VL) testing is an essential component of the
care of HIV-positive individuals, both with regard to
timing of initiation of antiretroviral therapy (ART) and
to monitoring of virologic response to combination
ART (cART) [1]. The goal of cART is sustained virolo-
gic suppression, defined as a VL below the level of
detection of the test performed [1]. Guidelines
recommend that HIV-positive individuals receive VL
testing at intervals of three to four months as standard
of care [1]. CD4 count monitoring is important for
deciding when to start cART and for determining prog-
nosis, but alone is insufficient as a marker of treatment
efficacy as it does not identify individuals experiencing
virologic rebound or failure [2]. Early determination of
virologic rebound and failure is one of the most crucial
components of HIV management as it contributes to
the reduction of ART drug resistance [3]. Lastly,* Correspondence: raboud@lunenfeld.ca
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VL monitoring has also been shown to promote treat-
ment adherence, which is additionally important for
maintaining virologic suppression and reducing the evo-
lution of drug resistance [4].
Access to VL testing has been studied previously. In
an Ontario cohort, injection drug use, younger age and
residence in Toronto were associated with lower VL
testing rates [5]. In another study, drug users were also
found to be at risk for irregular VL monitoring [6]. In a
study of individuals who initiated ART between 1994
and 2000, individuals with low CD4 counts and high
VLs had the highest rates of laboratory testing [7].
In this study, we examine whether there are regional
differences in patterns of VL testing among individuals
who initiated cART therapy since January 1, 2000 in
Canada, where VL testing is available without charge to
all HIV-positive residents as part of the provincial uni-
versal health insurance plans. Furthermore, we identified
demographic and clinical factors associated with subop-
timal frequency of VL testing.
Methods
The Canadian Observational Cohort (CANOC) colla-
boration is a Canadian cohort study of antiretroviral
naïve HIV-positive patients initiating cART since Janu-
ary 1st 2000. The study was established in March 2008
with funding from the Canadian Institutes of Health
Research (grant# 711098) and the CIHR Canadian HIV
Trials Network (CTN242) and includes cohorts and
investigators from across the country (listed at the end
of the manuscript). The collaboration is open to all
Canadian HIV treatment cohorts with more than 100
eligible patients.
Participating cohorts
Data used in this analysis were from nine cohorts of
HIV-positive individuals in British Columbia (BC),
Ontario, and Quebec, including the BC Centre for
Excellence in HIV/AIDS Drug Treatment Program,
Montreal Chest Institute Immunodeficiency Cohort,
The Electronic Antiretroviral Therapy, Clinique Médi-
cale l’Actuel, The Canadian HIV/HCV Co-infection
Cohort, Ontario Cohort Study, Maple Leaf Medical
Clinic, Toronto General Hospital and Ottawa Hospital
HIV/HCV Cohort [8].
Patient selection and data extraction were performed
at the data centres of the participating cohort sites. In
provinces with multiple cohorts, VL data were entered
from each cohort site and not from a provincial data
source. Non-nominal data from each cohort on a prede-
fined set of demographic, laboratory, and clinical vari-
ables were then pooled and analyzed at the Project Data
Centre in Vancouver. All participating cohorts have
received approval from their institutional ethics boards
and governance committees to contribute non-nominal
patient-specific data to CANOC. Ownership of indivi-
dual cohort data remains with the contributing cohort
and cohort data can only be used for studies approved
by the CANOC Steering Committee.
Eligibility Criteria
Eligibility criteria for inclusion in CANOC were docu-
mented HIV infection, residence in Canada, aged 18
years and over, initiation of three or more antiretroviral
drugs for the first time (i.e. ART-naïve cART start) after
January 1, 2000, and a viral load measurement and CD4
cell count within 6 months of the start of therapy. To
be included in this analysis, individuals had to have at
least one year of follow-up. Viral load measurements
were available both before and after starting cART.
Statistical Methods
Three measures were used to assess the frequency of VL
testing. First, the primary outcome of interest was
defined as a gap between VL tests in excess of 9 months,
corresponding to at least three missed or delayed tests
assuming the optimal frequency between tests is three
months. This was felt to be a clinically important gap in
VL testing. Second, the annual rate of VL testing was
calculated by dividing the total number of tests for an
individual by the duration of follow-up for that indivi-
dual in years. Third, the time interval, defined as the
number of days between two successive VL tests for a
subject, was examined.
Demographic and clinical characteristics such as gen-
der, race, HIV risk factors, age, geographic region, CD4
count and type of cART regimen were compared among
regions with chi square tests for categorical variables
and Wilcoxon rank sum tests for continuous variables.
The proportion of individuals with at least one subop-
timal interval and the annual rate of VL testing experi-
enced were compared among regions and by
demographic and clinical characteristics with the chi
square test and Wilcoxon rank sum test respectively.
Generalized Estimating Equation (GEE) logistic regres-
sion models, which account for correlation among mul-
tiple observations within subjects, were used to
determine factors associated with the occurrence of a
suboptimal testing interval[9]. An exchangeable correla-
tion structure was assumed for this model. As a form of
sensitivity analysis, we repeated the analysis by defining
a suboptimal interval as six months or more, corre-
sponding to at least two missed or delayed tests if the
optimal frequency between tests is three months.
The relationships between the length of the VL inter-
test interval and individual characteristics were exam-
ined using GEE linear regression models. Plasma VL
levels, CD4 counts, characteristics of the antiretroviral
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regimen and the calendar year of VL tests were treated
as time-varying covariates in all regression models. Cov-
ariates with a p < 0.10 in the univariate regression mod-
els were considered as candidates for inclusion in the
multivariable model.
Data cleaning
When there was a gap between two consecutive VL
tests in excess of nine months, the accompanying CD4
test dates were examined to validate the VL test dates.
Viral load tests within 8 days of each other and with
results within 0.1 log10 copies/mL were considered to be
duplicate measurements. In such cases, the first VL date
was kept and the average of the VL measurements was
assigned as the VL value.
Results
Study cohort and overall VL testing
3,648 subjects met cohort inclusion criteria. Demo-
graphic characteristics are described by region in
Table 1. The median number of VL tests and the med-
ian length of follow-up were 15 (interquartile range
(IQR) [9-13][14-22]) and 42.9 months (IQR [25.4-64.4]),
respectively. The median rate of testing was 4.3 VL
measurements per year (IQR [3.4-5.5]). On average, 83%
of the population had more than 3 tests per year and
58% had more than 4 tests per year. Of 57,308 intervals
between VL tests, 2.3% were > 9 months and 6.8% were
> 6 months. The median annual rates of VL testing
were 4.9 (IQR [3.8-6.3]) in BC, 3.9 (IQR [3.1-4.8]) in
Ontario and 4.0 (IQR [3.2-4.8]) in Quebec.
Table 1 Comparison of Baseline Demographic and Clinical Characteristics by Region
Region
Characteristics Total (n = 3648) BC (n = 1674) Ontario (n = 1143) Quebec (n = 831) p value
Age 40 (34-46) 40 (34-47) 39 (34-45) 40 (34-46) <0.01
Male 2925 (80%) 1328 (79%) 934 (82%) 663 (80%) 0.28
Race†
Caucasian 956 (52%) 552 (45%) 309 (50%) 95 (84%) <0.0001
Black 181 (10%) 31 (3%) 138 (26%) 12 (11%)
First Nation 121 (7%) 103 (9%) 15 (3%) 3 (3%)
Mixed 465 (25%) 464 (38%) 1 (<% 0 (0%)
Other 128 (7%) 66 (5%) 59 (11%) 3 (3%)
Missing 1837 497 622 718
Risk factor‡
MSM 1015 (34%) 203 (12%) 362 (66%) 450 (60%) <0.0001
IDU 632 (21%) 442 (26%) 82 (13%) 108 (14%) <0.0001
Heterosexual 486 (16%) 98 (6%) 188 (35%) 200 (27%) <0.0001
Endemic country 233 (19%) 0 (0%) 92 (20%) 141 (19%) 0.52
Blood product recipient 43 (1%) 10 (1%) 25 (6%) 8 (1%) <0.0001
Other/Missing 1554 (43%) 961 (57%) 569 (45%) 147 (9%) <0.0001
AIDS defining illness 481 (13%) 259 (15%) 115 (10%) 107 (13%) <0.001
cART initiation date 2003 (2001-05) 2003 (2001-05) 2004 (2002 - 05) 2004 (2002-05) <0.0001
Type of cART
NNRTI-based 1586 (43%) 753 (45%) 512 (45%) 321 (39%) <0.0001
Boosted PI-based 1433 (39%) 726 (43%) 397 (35%) 310 (37%)
Single PI-based 384 (11%) 151 (9%) 137 (12%) 96 (12%)
Other cART 245 (7%) 44 (3%) 97 (8%) 104 (13%)
CD4 count (cells/mm3) 190 (100-277) 170 (80-260) 202 (107-296) 208 (127-290) <0.0001
CD4 count category
<200 cells/mm3 1921 (53%) 981 (59%) 555 (49%) 385 (47%) <0.0001
200 - 350 cells/mm3 1175 (32%) 486 (29%) 374 (33%) 315 (38%)
> 350 cells/mm3 544 (15%) 207 (12%) 212 (19%) 125 (15%)
VL (log10 copies/mL) 4.9 (4.4-5.1) 5.0 (4.6-5.0) 4.8 (4.3-5.3) 4.8 (4.2-5.2) <0.01
VL <50 copies/mL 139 (4%) 56 (3%) 48 (4%) 35 (4%) 0.40
Hepatitis C co-infection 736 (30%) 501 (44%) 124 (22%) 111 (15%) <0.0001
MSM = men who have sex with men, IDU = injection drug user, cART = combination antiretroviral therapy, NNRTI = non nucleoside reverse transcriptase
inhibitor, PI = protease inhibitor, VL = viral load.
†Race percentages are calculated as percentages of non-missing values. ‡Risk factors are not mutually exclusive. Results are N (%) or median (interquartile range).
Missing values are only reported for variables with more than 25% missing data.
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Analysis of the annual rate of VL testing
In univariate analyses, higher annual rates of VL testing
were associated with residence in BC, age > 40 years,
white race, male gender, later year of cART initiation,
pretreatment VL ≥ 105 copies/mL, an HIV risk category
of “men who have sex with men” (MSM), history of an
AIDS-defining illness, boosted-protease inhibitor (PI)-
based cART regimen, not being co-infected with Hepati-
tis C and not being an injection drug user (IDU)
(Table 2).
Analysis of gaps of greater than nine months and six
months
Of the 3,648 patients eligible for the analysis, 26% and
51% of the population had experienced at least one
nine-month and one six-month gap during their follow-
up, respectively. Proportions of patients with at least
one nine-month gap and with at least one six-month
gap are shown by demographic and clinical characteris-
tics in Table 2. Results of univariate GEE logistic regres-
sion models are shown in Table 3. In the multivariable
GEE logistic regression model (Table 4), gaps of both
nine and six months were significantly more likely to
occur in Ontario and Quebec and among IDUs. Gaps of
both nine and six months were significantly less likely
to occur among older individuals, among MSM, in
recent calendar years of VL test, among individuals on
cART, in the first year of cART and if the VL had been
suppressed at the previous visit.
Analysis of the time interval between successive tests
In univariate GEE linear regression models, covariates
which were associated with a decrease in the number
of days between VL tests included age, male gender,
later year of initiating cART, being within the first year
of cART, receiving PI-boosted cART regimen, higher
baseline VL and having been diagnosed with an AIDS-
defining illness (Table 3). Covariates which were asso-
ciated with an increase in the number of days between
VL tests included living in Quebec or Ontario com-
pared to living in BC, not being on cART, having
more drugs in the cART regimen, higher baseline CD4
count, being an IDU and having a suppressed VL at
the previous test. The predicted time interval between
successive tests was 85 days for a 40 year old patient
living in BC who started cART between 2002 and
2004, had completed the first year of a boosted-PI
based cART regimen, with the most recent VL below
the limit of detection, being neither a MSM nor an
IDU, and taking cART at the current VL test (Table
4). The predicted time intervals would be 104 or 105
days for a similar patient in Ontario or Quebec,
respectively.
Discussion
There was considerable regional variation in annual
rates of VL measurement documented in this Canada-
wide study. This variation remained significant even
after adjusting for demographic variables such as age
and HIV risk factors and clinical variables such as year
of cART initiation, type of cART regimen, being in the
first year of cART, AIDS-defining illness and whether or
not the previous VL was below the limit of detection. In
Ontario and Quebec, VL was measured quarterly on
average. In BC, rates of VL measurement were even
more frequent than guidelines suggest, with an average
measurement frequency of almost five times annually.
There are a number of possible explanations for the
regional differences in rates of viral load measurement.
Some of the difference in measurement rate was due to
regional differences in demographic factors such as the
proportions of IDUs, who typically have less frequent
viral load testing, or pregnant women, in whom viral
load is monitored more closely. Further differences
could be due to variation in rates of VL blips among
regions, after which a repeat VL measurement is typi-
cally ordered. Recent data has documented differing
rates of blips by VL assay [10,11] and this may explain
the higher rates of testing in BC. Regional differences in
VL testing policies may also have an impact. While
there are no differences among provinces in the official
guidelines for the frequency of VL measurement, it is
possible that there are differences in the implementation
of the guidelines. In Ontario, a VL will not be per-
formed by the laboratory if one has been done within
the last 14 days. Furthermore, rates of VL measurement
may be higher in British Columbia due to the fact that
all antiretroviral drug distribution and VL testing is
coordinated through a single center in the province.
Lastly, differences in participation rates among provinces
in research studies, which may require more frequent
VL testing may explain some of regional variation.
Effective therapy should result in at least a 90% or
10-fold (1.0 log10 copies/mL) decrease in plasma VL in
the first month and suppression to below 50 copies/mL
by 24 weeks, depending on the pretreatment VL level
[1]. Current guidelines suggest once VL suppression to
below 50 copies/mL is confirmed, it should be assessed
at regular intervals (e.g. every 3 or 4 months). Isolated
episodes of low-level viremia ("blips”) are not necessarily
predictive of subsequent virologic failure, but consistent
elevations of VL above 50 copies/mL meet a strict defi-
nition of virologic failure. Emergence of a detectable VL
in a previously suppressed patient (i.e. previously consis-
tently < 50 copies/mL) mandates re-evaluation of the
case, including repeated testing to confirm whether this
represents a “blip” or virologic failure. Confirmed VL
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Table 2 Annual rates of viral load testing and proportions of participants with gaps in testing by baseline
demographic and clinical characteristics
annual rate of VL testing Subjects having ≥ 1 gap of >9 months Subjects having ≥ 1 gap of >6 months
Characteristics N median (IQR) p value # (%) p value # (%) p value
Overall 3648 4.3 (3.4-5.5) 943 (26%) 1848 (51%)
Region
BC 1674 4.9 (3.8-6.3) <.0001 347 (21%) <.0001 672 (40%) <.0001
Ontario 1143 3.9 (3.1-4.8) 357 (31%) 699 (61%)
Quebec 831 4.0 (3.2-4.8) 239 (29%) 477 (57%)
Age (years)
≤ 40 1942 4.1 (3.2-5.3) <.0001 614 (32%) <.0001 1122 (58%) <.0001
> 40 1706 4.5 (3.6-5.8) 329 (19%) 726 (43%)
Gender
Female 723 3.9 (3.1-5.0) <.0001 255 (35%) <.0001 475 (66%) <.0001
Male 2925 4.4 (3.5-5.7) 688 (24%) 1373 (47%)
Caucasian
No 855 4.4 (3.4-5.7) 0.33 255 (30%) 0.04 463 (54%) <.001
Yes 956 4.4 (3.4-5.9) 244 (26%) 439 (46%)
Risk Factor
IDU 632 4.0 (3.0-5.1) <.0001 247 (39%) <.0001 417 (66%) <.0001
MSM 976 4.3 (3.5-5.4) 186 (19%) 421 (43%)
Blood product recipient 32 4.1 (3.5-5.1) 8 (25%) 18 (56%)
Endemic 209 4.1 (3.4-4.8) 60 (29%) 128 (61%)
Heterosexual contact 245 4.2 (3.4-5.7) 64 (26%) 135 (55%)
Not reported/Other 1554 4.5 (3.4-5.8) 378 (24%) 729 (47%)
AIDS defining illness
No 3167 4.2 (3.3-5.5) <.0001 858 (27%) <.0001 1641 (52%) <.001
Yes 481 4.7 (3.8-5.9) 85 (18%) 207 (43%)
Type of cART
NNRTI-based 1586 4.1 (3.2-5.0) <.0001 425 (27%) <.0001 874 (55%) <.0001
Boosted PI-based 1433 5.0 (3.7-6.5) 292 (20%) 573 (40%)
Single PI-based 384 4.0 (3.1-4.9) 149 (39%) 256 (67%)
Other cART 245 3.9 (3.2-4.7) 77 (31%) 145 (59%)
Year of initiating cART
2000 482 3.7 (2.8-4.7) <.0001 219 (45%) <.0001 346 (72%) <.0001
2001-2004 2036 4.2 (3.3-5.3) 599 (29%) 1132 (56%)
>2004 1130 4.9 (3.9-6.4) 125 (11%) 370 (33%)
CD4 count
<200 cells/mm3 1921 4.4 (3.4-5.7) <.0001 474 (25%) <.001 941 (49%) <.0001
200 - 350 cells/mm3 1175 4.3 (3.4-5.5) 286 (24%) 560 (48%)
> 350 cells/mm3 544 4.1 (3.0-5.2) 181 (33%) 341 (63%)
VL (copies/mL)
≥ 50 3509 4.3 (3.4-5.6) <.001 905 (26%) 0.68 1770 (50%) 0.19
<50 139 3.9 (2.9-4.8) 38 (27%) 78 (56%)
Hepatitis C Co-infection
No 1712 4.4 (3.6-5.6) <.0001 346 (20%) <.0001 756 (44%) <.0001
Yes 736 4.1 (3.0-5.3) 281 (38%) 473 (64%)
MSM = men who have sex with men, IDU = injection drug use, cART = combination antiretroviral therapy, NNRTI = non nucleoside reverse transcriptase
inhibitor, PI = protease inhibitor.
† Risk factors were grouped hierarchically for comparison purposes: IDU, MSM, blood product recipient, origin/residence in an HIV-endemic area, heterosexual
transmission.
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rebound should prompt a careful evaluation of regimen
tolerability, drug-drug interactions, resistance and
patient adherence. CD4+ cell counts should generally be
assessed in concert with VL.
In terms of the demographic findings, our findings are
similar to those of the study conducted in Ontario sev-
eral years ago and could likely be generalizable to other
settings with universal health care programs. In settings
with user-pay programs for virologic monitoring, it
seems likely that socioeconomic factors will have a
considerably greater influence on rates of testing. In
resource limited settings, availability and travel distances
are likely to remain significant barriers to regular moni-
toring of VL levels.
Our results have important implications for guidelines
and for research into the monitoring of VL. For patients
for whom VL is measured less frequently, virologic
rebound will be detected later on average and patients
will remain on failing regimens longer than is necessary.
In some circumstances, however, it is safe to measure
Table 3 Univariate GEE regression models of interval (days), probability of >9 and >6 months between viral load
measurements
Interval (days) Gaps of >9 months Gaps of >6 months
Covariates Estimate (95% CI) p value OR (95% CI) p value OR (95% CI) p value
Region
Quebec 24.1 (20.2, 28.0) <.0001 1.65 (1.37, 1.98) <.0001 1.71 (1.50, 1.96) <.0001
Ontario 25.6 (22.2, 28.9) <.0001 1.77 (1.51, 2.08) <.0001 2.14 (1.90, 2.41) <.0001
BC (reference) 0 1 1
Age (per 10 years) -7.0 (-8.6, -5.3) <.0001 0.70 (0.65, 0.76) <.0001 0.76 (0.72, 0.81) <.0001
Male -12.9 (-16.9, -8.8) <.0001 0.58 (0.50, 0.68) <.0001 0.62 (0.55, 0.69) <.0001
Caucasian -2.1 (-6.6, 2.4) 0.36 0.78 (0.64, 0.95) 0.01 0.83 (0.71, 0.97) 0.02
Risk factor
MSM 2.2 (-1.1, 5.6) 0.19 0.74 (0.61, 0.89) <.01 0.86 (0.75, 0.97) 0.02
IDU 18.5 (13.1, 23.9) <.0001 2.06 (1.74, 2.44) <.0001 1.80 (1.58, 2.04) <.0001
Heterosexual 14.3 (9.4, 19.3) <.0001 1.55 (1.26, 1.89) <.0001 1.57 (1.36, 1.81) <.0001
Endemic country -0.1 (-6.3, 6.1) 0.98 1.05 (0.79, 1.39) 0.74 1.08 (0.89, 1.31) 0.44
Blood products 6.3 (-3.8, 16.4) 0.22 0.93 (0.52, 1.65) 0.79 1.19 (0.76, 1.89) 0.45
Year of initiating cART
>2004 -31.0 (-37.4, -24.6) <.0001 0.36 (0.28, 0.46) <.0001 0.49 (0.41, 0.57) <.0001
2001-2004 -18.4 (-24.7, -12.1) <.0001 0.62 (0.52, 0.73) <.0001 0.70 (0.61, 0.80) <.0001
2000 (ref.) 0 1 1
1st year of cART -36.1 (-37.6, -34.6) <.0001 0.15 (0.13, 0.18) <.0001 0.27 (0.25, 0.30) <.0001
Type of cART
NNRTI-based 0 1 1
Boosted PI-based -16.7 (-20.0, -13.4) <.0001 0.76 (0.64, 0.89) <.001 0.71 (0.63, 0.80) <.0001
Single PI-based 5.4 (-0.3, 11.0) 0.06 1.37 (1.12, 1.68) <.01 1.19 (1.02, 1.40) 0.03
Other cART 6.2 (-0.2, 12.6) 0.06 1.17 (0.89, 1.53) 0.26 1.05 (0.86, 1.27) 0.65
Boosted PI (Y/N) -18.3(-21.4, -15.2) <.0001 0.70 (0.60, 0.81) <.0001 0.68 (0.61, 0.76) <.0001
On cART at current visit -32.2 (-34.9, -29.6) <.0001 0.31 (0.28, 0.35) <.0001 0.38 (0.35, 0.42) <.0001
On cART at previous visit -12.4 (-14.5, -10.3) <.0001 0.58 (0.52, 0.65) <.0001 0.65 (0.61, 0.70) <.0001
Baseline CD4 count
>350 cells/mm3 12.7 (7.8, 17.7) <.0001 1.43 (1.19, 1.72) <.001 1.51 (1.31, 1.74) <.0001
200-350 cells/mm3 2.7 (-0.7, 6.1) 0.12 0.94 (0.80, 1.10) 0.44 0.97 (0.86, 1.09) 0.57
<200 cells/mm3 (ref.) 0 1 1
Baseline VL <50 copies/mL 17.3 (7.2, 27.3) <.001 1.17 (0.82, 1.67) 0.38 1.47 (1.13, 1.90) <.01
Baseline VL (log10 copies/mL) -7.2 (-9.2, -5.3) <.0001 0.85 (0.79, 0.91) <.0001 0.84 (0.79, 0.88) <.0001
VL <50 copies/mL at previous test 18.3 (16.5, 20.0) <.0001 0.71 (0.64, 0.78) <.0001 1.18 (1.11, 1.26) <.0001
VL (log10 copies/mL) at previous visit -3.1 (-3.9, -2.3) <.0001 1.23 (1.18, 1.28) <.0001 1.02 (0.99, 1.04) 0.24
AIDS defining illness -14.1 (-17.5, -10.6) <.0001 0.53 (0.42, 0.68) <.0001 0.59 (0.50, 0.70) <.0001
Hepatitis C co-infection 17.9 (13.0, 22.7) <.0001 2.45 (2.06, 2.91) <.0001 1.98 (1.74, 2.26) <.0001
Positive for HCV antibodies 14.0 (9.3, 18.7) <.0001 2.13 (1.81, 2.50) <.0001 1.64 (1.45, 1.85) <.0001
MSM = men who have sex with men, IDU = injection drug use, cART = combination antiretroviral therapy, NNRTI = non nucleoside reverse transcriptase
inhibitor, PI = protease inhibitor, VL = viral load, HCV = hepatitis C virus.
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VL less frequently [12]. A reduced monitoring schedule
would result in cost savings due to both the cost of the
laboratory testing and the cost of the physician time. As
ART is a life-long commitment, cost considerations are
not insignificant. Further, less frequent VL monitoring
would reduce the inconvenience to the patient, which
may improve overall compliance. However, while it may
be safe and cost effective to extend the period between
VL measurements from three to six months in patients
with virologic suppression, periods in excess of nine
months are less easily justified and place patients at
unnecessary risk. Steps should be taken to facilitate
more careful VL monitoring in groups at high risk for
gaps in testing.
A strength of our study is that VL monitoring is pro-
vided free of charge to all HIV-positive individuals in
Canada, so that we were able to examine correlates of
rates of VL testing in the absence of financial barriers to
testing. Further, by combining data from nine sites
across Canada, we achieved a large sample size as well
as a good representation by region, gender, race, and
other demographic characteristics. CANOC represents
about a quarter of all HIV-positive people in the country
who are currently on ART and approximately half of
those who have initiated on more modern regimens
since 2000 [13]. This is the largest sample of HIV-posi-
tive people on ART compiled in Canada and represents
one of the most representative samples put together in a
high-income country. One limitation of this dataset is
that this information is not currently available on a
nation-wide basis, so regional differences in provinces
other than BC, Ontario and Quebec could not be exam-
ined. A further limitation is that data were missing on
race and HIV risk factors for many patients.
Future plans for investigation include further examina-
tion of the reasons for the regional differences in rates
of VL testing. Also, an economic analysis to determine
if the less frequent testing found in Ontario and Quebec
is adequate in terms of clinical outcomes and could
result in financial savings would be informative. Particu-
larly, an analysis of VL testing frequency in patients
with full virologic suppression where less testing may be
adequate would be of interest and its impact on cost
savings could be important.
Conclusions
In our setting, with universal health care and similar
regional guidelines for viral load testing, significant varia-
tion in rates of VL measurement and the probability of a
significant gap in testing were related to geographic
region, age, HIV risk factors and clinical variables such as
year of cART initiation, type of cART regimen, being in
the first year of cART, AIDS-defining illness and whether
or not the previous VL was below the limit of detection.
Table 4 Multivariate GEE regression models of testing intervals and of probability of >9 and >6 months between viral
load measurements
Interval (days) between successive
tests
Probability of an interval
>9 months
Probability of an interval
>6 months
Covariates Estimate (95% CI) p value Odds Ratio (95% CI) p value Odds Ratio (95% CI) p value
Intercept 125.8 (118.8, 132.9) <.0001 0.09 (0.07, 0.11) <.0001 0.20 (0.16, 0.23) <.0001
Region
Quebec 20.3 (15.5, 25.0) <.0001 1.72 (1.39, 2.14) <.0001 1.61 (1.37, 1.89) <.0001
Ontario 18.7 (14.3, 23.0) <.0001 1.78 (1.37, 2.31) <.0001 1.77 (1.47, 2.14) <.0001
BC 0 1 1
Age (per 10 years) -3.8 (-5.4, -2.2) <.0001 0.77 (0.70, 0.85) <.0001 0.77 (0.72, 0.83) <.0001
Risk factor
MSM -9.2 (-13.1, -5.4) <.0001 0.62 (0.49, 0.78) <.0001 0.66 (0.56, 0.77) <.0001
IDU 16.0 (11.1, 20.9) <.0001 1.68 (1.38, 2.05) <.0001 1.71 (1.48, 1.99) <.0001
Year of initiating cART
>2004 -15.8 (-21.9, -9.7) <.0001 0.62 (0.46, 0.83) 0.001 0.74 (0.60, 0.91) 0.005
2001-2004 -12.4 (-18.2, -6.6) <.0001 0.70 (0.57, 0.86) 0.0006 0.75 (0.64, 0.89) 0.0007
2000 (ref.) 0 1 1
1st year of cART -24.3 (-26.0, -22.6) <.0001 0.15 (0.12, 0.20) <.0001 0.32 (0.29, 0.36) <.0001
On cART at current visit -27.8 (-31.0, -24.6) <.0001 0.34 (0.29, 0.40) <.0001 0.40 (0.36, 0.45) <.0001
VL <50 copies/mL at previous test 8.6 (6.6, 10.7) <.0001 0.56 (0.48, 0.65) <.0001 0.90 (0.82, 0.98) 0.02
Boosted PI based cART -9.1 (-12.2, -6.0) <.0001 0.82 (0.71, 0.94) 0.006
AIDS defining illness -4.9 (-8.5, -1.4) 0.007
MSM = men who have sex with men, IDU = injection drug use, cART = combination antiretroviral therapy, VL = viral load, PI = protease inhibitor.
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